BlackRock Health Sciences Term Trust (NYSE:BMEZ) Plans Monthly Dividend of $0.18

BlackRock Health Sciences Term Trust (NYSE:BMEZ) announced a monthly dividend on Friday, December 6th,NASDAQ Dividends reports. Investors of record on Monday, December 16th will be paid a dividend of 0.1781 per share on Monday, December 23rd. This represents a $2.14 dividend on an annualized basis and a yield of 13.81%. The ex-dividend date of this dividend is Monday, December 16th.

BlackRock Health Sciences Term Trust has raised its dividend by an average of 20.7% per year over the last three years.

BlackRock Health Sciences Term Trust Trading Down 0.1 %

BMEZ stock traded down 0.02 during mid-day trading on Friday, reaching 15.48. 360,200 shares of the stock traded hands, compared to its average volume of 277,112. BlackRock Health Sciences Term Trust has a one year low of 14.38 and a one year high of 16.59. The business has a 50-day moving average price of 15.61 and a two-hundred day moving average price of 15.62.

Insider Buying and Selling

In other BlackRock Health Sciences Term Trust news, major shareholder Saba Capital Management, L.P. bought 29,795 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was acquired at an average cost of 15.81 per share, for a total transaction of 471,058.95. Following the completion of the transaction, the insider now owns 20,750,913 shares in the company, valued at 328,071,934.53. This trade represents a 0.14 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders bought 99,630 shares of company stock valued at $1,585,113.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.